Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains

Diagnostic Microbiology and Infectious Disease
Dayane C SilvaM C Melhem

Abstract

There are few reports concerning the in vitro antifungal susceptibility of clinical and environmental Cryptococcus gattii isolates. In this study, we performed polymerase chain reaction-restriction fragment length polymorphism to investigate the molecular subtypes of 50 clinical and 4 environmental Brazilian isolates of C. gattii and assessed their antifungal susceptibility for fluconazole (FLU) and amphotericin B (Amb) according to recent recommendations proposed for antifungal susceptibility testing of nonfermentative yeasts. Time-kill curve studies were performed using RPMI 1640 medium to analyze the fungicidal effect of AmB. We found 47 VGII (94%) molecular types and 3 VGI (6%) types among the clinical isolates. The environmental isolates were VGII (75%) subtype and VGI (25%) subtype. The FLU-MIC ranged from 1 to 64 mg L(-1), and MIC(50)/MIC(90) values were, respectively, 8/16 mg L(-1). For AmB, the MICs were low and homogeneous, ranging from 0.12 to 0.5 mg L(-1), for VGI or VGII. The time required to reach the fungicidal end point (99.9% killing) was 6 h for the majority of strains (64%), but viable cells of VGII were still present after 48 h of exposition. We pointed out the occurrence of high FLU-MICs for C. gattii isola...Continue Reading

References

Jul 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·B Speed, D Dunt
Mar 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D H MitchellT Gottlieb
Apr 1, 1995·Antimicrobial Agents and Chemotherapy·J H RexE J Anaissie
Mar 24, 2000·Diagnostic Microbiology and Infectious Disease·Y C ChenW C Hsieh
May 19, 2000·Antimicrobial Agents and Chemotherapy·A I AllerA Espinel-Ingroff
Jun 20, 2000·Antimicrobial Agents and Chemotherapy·M E KlepserM A Pfaller
Apr 3, 2001·Microbiology·T BoekhoutW Meyer
May 16, 2003·FEMS Yeast Research·Agnes Kiesling CasaliMarilene Henning Vainstein
Jun 25, 2004·Antimicrobial Agents and Chemotherapy·Emilia CantónAna Espinel-Ingroff
Oct 9, 2004·Journal of Clinical Microbiology·Luciana TrillesJosep Guarro
Dec 2, 2004·Proceedings of the National Academy of Sciences of the United States of America·S E KiddW Meyer
May 6, 2005·Journal of Clinical Microbiology·M A PfallerD J Diekema
Jun 28, 2006·Antimicrobial Agents and Chemotherapy·E DannaouiUNKNOWN French Cryptococcosis Study Group
Sep 20, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Juliette MorganUNKNOWN Gauteng Cryptococcal Surveillance Initiative Group
Mar 21, 2007·Emerging Infectious Diseases·Laura MacDougallKaren H Bartlett
Mar 27, 2007·Revista Do Instituto De Medicina Tropical De São Paulo·Marcelo Teruyuki MatsumotoMaria José Soares Medes-Giannini
Jan 15, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·UNKNOWN Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility T
Apr 1, 2008·The Journal of Antimicrobial Chemotherapy·Josep M Torres-RodríguezMaite Sellart
Jun 19, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A Gomez-LopezM Cuenca-Estrella
Oct 29, 2008·Antimicrobial Agents and Chemotherapy·George R ThompsonThomas F Patterson
Dec 17, 2008·Revista Do Instituto De Medicina Tropical De São Paulo·Mariceli Araujo Ribeiro, Popchai Ngamskulrungroj
Apr 7, 2009·Diagnostic Microbiology and Infectious Disease·Mara C S M PappalardoMarcia S C Melhem
Apr 14, 2010·Antimicrobial Agents and Chemotherapy·A Varma, K J Kwon-Chung
Jan 20, 2011·Antimicrobial Agents and Chemotherapy·Oscar ZaragozaManuel Cuenca-Estrella
Jun 21, 2011·Microbes and Infection·Edmond J ByrnesJoseph Heitman

❮ Previous
Next ❯

Citations

Jun 3, 2014·BMC Microbiology·Erin J KelleyDavid M Engelthaler
Dec 18, 2012·Current Fungal Infection Reports·Deborah J SpringerJoseph Heitman
Feb 28, 2015·Fungal Genetics and Biology : FG & B·Ferry HagenTeun Boekhout
Jul 16, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Monica ChanTim Barkham
Oct 4, 2014·Clinical Microbiology Reviews·Sharon C-A ChenTania C Sorrell
May 3, 2016·Mycoses·Franqueline Reichert-LimaAngelica Z Schreiber
Aug 2, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P F HerkertF Queiroz-Telles
Oct 27, 2018·Revista Do Instituto De Medicina Tropical De São Paulo·Thaísa Cristina SilvaMaria do Rosário Rodrigues Silva
Aug 15, 2013·Mycopathologia·Pedro Henrique Magalhães CardosoClaudete Rodrigues Paula
Apr 12, 2018·Memórias do Instituto Oswaldo Cruz·Carolina FiracativeUNKNOWN Latin American Cryptococcal Study Group
Apr 7, 2021·G3 : Genes - Genomes - Genetics·Corinne MaufraisGuilhem Janbon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Alzheimer's Disease: Genetics

Alzheimer's disease is a neurodegenerative disease. Discover genetic and epigenetic aspects of Alzheimer’s disease, including genetic markers and genomic structural variations with this feed.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.